<DOC>
	<DOCNO>NCT01656993</DOCNO>
	<brief_summary>Background : Blood clot cause poor outcome , include death , baby heart defect require surgical connection ( `` shunt '' ) provide blood flow lung . Aspirin ( ASA ) block part blood help clot form ( platelet ) . Aspirin use baby shunt prevent blood clot . The dose aspirin give baby base adult research . Because baby different adult , investigator know dose enough block platelet , much may cause bleeding . The investigator test platelet use blood test call Thromboelastography Platelet Mapping ( TEG-PM ) . This test need small amount blood use baby . Hypothesis Specific Aims : The investigator suspect aspirin dos typically give baby enough block platelet prevent blood clot shunt . The investigator want determine percentage baby whose platelet block enough ( &lt; 70 % inhibition ) , use TEG-PM . The investigator also want determine often bleed clot occur baby receive aspirin .</brief_summary>
	<brief_title>Antiplatelet Activity Aspirin Infants After Aortopulmonary Cavopulmonary Shunts</brief_title>
	<detailed_description>Background : Aortopulmonary cavopulmonary shunt ( `` shunt '' ) surgically place provide pulmonary blood flow infant congenital heart disease require shunt survival . Thrombosis occur 17 % shunted infant ( Li et al , 2007 ; Monagle et al , 2012 ) associate morbidity 23 % mortality 7 % . ( Li et al , 2007 ) One study report third death shunt thrombosis . ( Fenton , 2003 ) Despite insufficient evidence guide appropriate dosing , current thromboprophylaxis guideline recommend aspirin ( ASA ) thrombus prevention high-risk infant . No therapeutic monitoring exist ensure consistent effective anticoagulation prevent over-anticoagulation minimize bleeding complication . Previous study examine effectiveness ASA shunt thrombosis prevention conflict result . The recent large , prospective observational study show significant association ASA use low risk thrombosis death ( Li et al , 2007 ) , study limit lack standardized ASA dosing failure include adverse event . To complicate picture , adult study describe phenomenon term `` ASA resistance , '' thrombosis occur despite ASA therapy . ( Frelinger et al , 2008 ; Heistein et al , 2008 ; Szczeklik et al , 2005 ; Frelinger et al , 2006 ) ASA resistance adequately study pediatric population lead knowledge gap therapeutic dosing adequate prevention thrombosis combine minimization bleed complication . Thromboelastography Platelet Mapping ( TEG-PM ) blood test specifically evaluate percentage inhibition arachidonic acid pathway target ASA . It use serial monitoring adequacy anticoagulation ASA shunt infant provide evidence safe effective dosage use pediatric population . Hypothesis Specific Aims : Hypothesis : The investigator hypothesize ASA dose current guideline ( 1-5 mg/kg/day ) favor protection bleed complication fails achieve adequate inhibition arachidonic acid pathway prevent thrombosis . Specific Aim 1 : The primary aim determine percentage infant treat ASA shunt surgery adequate ( &gt; 70 % ) inhibition arachidonic acid pathway measure TEG-PM . Outcome : The percentage arachidonic inhibition , measure TEG-PM , 3 designate time point start ASA postoperatively . Therefore , TEG-PM measure designated time point : 1 . After third dose ASA 2 . At first post-operative cardiology clinic visit ( 2 4 week hospital discharge ) 3 . At follow-up cardiology clinic visit 3-6 month initiation ASA Specific Aim 2 : The secondary aim describe frequency bleed thrombotic event ASA . Outcome : The number bleed thrombotic event initiation ASA therapy end study document . ASA administration : ASA initiate cardiac intensive care unit attend physician postoperatively , dose 1-5 mg/kg/day , less 20 mg per day ; initiation ASA 1-5 mg/kg/day standard care recommend College Chest Physicians ( Monagle et al , 2012 ) , albeit limited evidence use . TEG-PM result obtain research purpose available research team . The dose ASA adjust result research TEG-PM . However , bleed thrombosis occurs , TEG-PM obtain local practice ASA dose adjust treat physician . If dose ASA change patient hospitalize , TEG-PM obtain 2 hour third ( adjust restart ) dose .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Undergoing cardiac surgery shunt plan treatment aspirin Age 2.0 day 12 month Consent parent guardian Known suspect congenital acquired coagulation disorder ( hemophilia , von Willebrands disease , Glansmans thrombasthenia ) . History aspirin use within 7 day surgery . Platelet count &lt; 50K prior surgery . Weight &lt; 2.5 kg . Prematurity define gestational age &lt; 37 week .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Aspirin</keyword>
	<keyword>ASA</keyword>
	<keyword>aortopulmonary shunt</keyword>
	<keyword>cavopulmonary shunt</keyword>
	<keyword>shunt</keyword>
	<keyword>TEG</keyword>
	<keyword>Antiplatelet</keyword>
</DOC>